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Chronic inﬂammation of the lung, as a consequence of persistent bacterial infections
by several opportunistic pathogens represents the main cause of mortality and
morbidity in cystic ﬁbrosis. Mechanisms leading to increased susceptibility to
bacterial infections in CF are not completely known, although the involvement
of cystic ﬁbrosis transmembrane conductance regulator (CFTR) in microbicidal
functions of macrophages is emerging. Tissue macrophages differentiate in situ
from inﬁltrating monocytes, additionally, mature macrophages from different tis-
sues, although having a number of common activities, exhibit variation in some
molecular and cellular functions. In order to deﬁne possible intrinsic macrophage
defects due to CFTR deﬁciencies we have analyzed the bactericidal activity against
P. aeruginosa of human monocyte derived macrophages from CF patients. First, by
real time PCR, immunoﬂuorescence and patch clamp recordings we demonstrated
CFTR expression and functional activity in control macrophages. Subsequently,
we evaluated the bactericidal activity of control and CF macrophages infected
by P. aeruginosa. Our results demonstrate that control and CF macrophages do
not differ in the phagocytic activity but, although a reduction of intracellular live
bacteria was detected in both groups, the percentage of surviving bacteria was
signiﬁcantly higher in CF macrophages. These ﬁndings further support the role of
CFTR in the bactericidal activity of innate immune cells.
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Background: Autoantibodies against the neutrophil derived bactericidal/
permeability increasing protein (BPI-ANCA) have been shown to exhibit a strong
correlation with lung function impairment among CF patients chronically colonized
with Pseudomonas aeruginosa (Pa). However, the test has never been compared with
different serological assays for Pa colonization.
Methods: After informed consent all non-transplanted CF patients belonging to the
CF centre in Lund, Sweden, who could perform standard spirometry were included
in the study. Bacterial colonisation was classiﬁed according to the Leeds criteria.
IgA and IgG BPI-ANCA was measured with ELISA and results were compared to
commercially available assays for Exotoxin A, Alkaline proteas and Elastas.
Results: BPI-ANCA was measured in 118 patients, of whom 51 (43%) were
classiﬁed as chronically colonized with Pa. The median age in the chronically
colonized group was 20.2 years and 17 patients (33.3%) were below the age of 18.
One patient was too young to have the FEV1% calculated. The median FEV1.0
was 63% of predicted. Overall the serology tests correlated better to each other
(r values: 0.39; 0.46 and 0.56) than they did with IgA-BPI-ANCA (r values: 0.02;
0.14 and 0.22). The correlation between serological test results and lung function
impairment (100-FEV1.0%) was 0.45 for BPI-ANCA compared with 0.08 (exo),
0.24 (ela) and 0.39 (alk pr) for the three bacteriological tests.
Conclusion: BPI-ANCA measures something different from regular serological
tests and seems to correlate better with disease severity.
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Background: YKL-40 − a chitinase-like protein − was increased in patients with
severe asthma and chronic obstructive pulmonary disease (COPD). Neutrophils
secrete YKL-40. We hypothesized that increased YKL-40 levels in lung diseases
reﬂect neutrophilic inﬂammation and that YKL-40 accumulates in the airways of
cystic ﬁbrosis patients (CF), a prototypic neutrophilic airway disease.
We aimed to analyze YKL-40 levels in human and murine CF lung disease
compared to COPD, asthma and control subjects.
Methods: YKL-40 protein levels were measured in serum and sputum samples of
CF, asthma, COPD and healthy individuals. Protein levels of the murine homologue
BRP-39 were quantiﬁed in airway ﬂuids from CF-like bENaC-Tg mice.
Results: YKL-40 levels were signiﬁcantly increased in human and murine CF air-
way ﬂuids compared to asthma, COPD and healthy individuals. In both CF patients
and bENaC-Tg mice, YKL-40/BRP-39 airway levels correlated with severity of
obstructive lung disease.
Conclusion: YKL-40 is increased in CF airway ﬂuids and is negatively associated
with pulmonary function. These ﬁndings suggest YKL-40 as potential biomarker
and therapeutic target in CF lung disease.
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Increased levels of Reactive Oxygen Species (ROS) and Tissue Transglutaminase
(TG2) SUMOylation are present in CF airway, leading to persistence of high TG2
levels. This drives cross-linking and aggresome accumulation of TG2 substrate
proteins, as PPARg and beclin1, leading to inhibition of autophagy and airway
inﬂammation. ROS scavengers or TG2 inhibitors restore the cellular homeostasis
by rescuing autophagy, controlling airway inﬂammation and favoring surface local-
ization of mutant CFTR [1].
Objectives: Our aim is to demonstrate the efﬁcacy of a-lipoic acid (aLA), already
reported as an antioxidant which is also involved in autophagy [2], in controlling
airway inﬂammation in vitro and in vivo in CF animal models [1].
Methods: IB3−1 and C38 cells were added with 500 mM aLA. CF mice and control
littermates were administered with aLA (100mg/kg i.p. for 7 days). MIP2, adhesion
molecules, inﬂammatory cytokines were assessed by ELISA; TG2, PPARg proteins
by western blots, TG2 SUMOylation and activity and leukocyte inﬁltration by
confocal microscopy and FRET both in vitro and in vivo.
Results: aLA decreased TG2 SUMOylation, TG2 protein and activity and increased
PPARg protein levels both in vitro and in vivo. Moreover aLA reduced MIP2 and
adhesion molecule (p< 0.005) and leukocyte inﬁltration (p< 0.05) in CF mice.
Conclusion: The treatment with aLA is effective in reducing sustained TG2
activation and their downstream effects in CF epithelia and in ameliorating airway
inﬂammation in CF mice. This could open the door for the implementation of a
new class of drugs to control chronic lung inﬂammation in CF patients.
Reference(s)
[1] Luciani A, Nature Cell Biol, 2010.
[2] Moreira PI, Autophagy 2007.
